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Summary
Background The rates of inﬂ uenza illness and associated complications are high among children in Bangladesh. 
We assessed the clinical eﬃ  cacy and safety of a Russian-backbone live attenuated inﬂ uenza vaccine (LAIV) at two ﬁ eld 
sites in Bangladesh.
Methods Between Feb 27 and April 9, 2013, children aged 2–4 years in urban Kamalapur and rural Matlab, Bangladesh, 
were randomly assigned in a 2:1 ratio, according to a computer-generated schedule, to receive one intranasal dose of 
LAIV or placebo. After vaccination, we monitored children in weekly home visits until Dec 31, 2013, with study clinic 
surveillance for inﬂ uenza illness. The primary outcome was symptomatic, laboratory-conﬁ rmed inﬂ uenza illness due 
to vaccine-matched strains. Analysis was per protocol. The trial is registered with ClinicalTrials.gov, number 
NCT01797029.
Findings Of 1761 children enrolled, 1174 received LAIV and 587 received placebo. Laboratory-conﬁ rmed inﬂ uenza 
illness due to vaccine-matched strains was seen in 93 (15·8%) children in the placebo group and 79 (6·7%) in the 
LAIV group. Vaccine eﬃ  cacy of LAIV for vaccine-matched strains was 57·5% (95% CI 43·6–68·0). The vaccine was 
well tolerated, and adverse events were balanced between the groups. The most frequent adverse events were 
tachypnoea (n=86 in the LAIV group and n=54 in the placebo group), cough (n=73 and n=43), and runny nose (n=68 
and n=39), most of which were mild.
Interpretation This single-dose Russian-backbone LAIV was safe and eﬃ  cacious at preventing symptomatic 
laboratory-conﬁ rmed inﬂ uenza illness due to vaccine-matched strains. LAIV programmes might reduce the burden 
of inﬂ uenza illness in Bangladesh.
Funding The Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
The seasonal patterns, incidence, and severity of 
inﬂ uenza virus infection are poorly deﬁ ned in many 
tropical regions.1 In Bangladesh, over a decade of 
surveillance data show that inﬂ uenza virus circulates 
during most months of the year and that infection is a 
frequent cause of febrile illness and lower respiratory 
tract infections in young children.2–7 Furthermore, in 
urban Kamalapur, which has a background clinical 
pneumonia incidence of 500 cases per 1000 child-years, 
community-based surveillance identiﬁ ed that 10% of 
children younger than 5 years with clinical pneumonia 
are positive for inﬂ uenza virus.4 Thus, prevention of 
inﬂ uenza illness could have a substantial eﬀ ect on 
childhood morbidity.
Live attenuated inﬂ uenza vaccines (LAIVs) are 
attractive for use in young children because they may be 
delivered intranasally and have good eﬃ  cacy. In a WHO-
sponsored technology transfer programme, several 
manufacturers are developing reassortant LAIVs based 
on A/Leningrad/17 and B/USSR/60 master donor 
viruses. This initiative could provide aﬀ ordable supplies 
of inﬂ uenza vaccine in Bangladesh and other low-
resource countries. In 2012, we did a phase 2 study 
involving 300 children aged 24–59 months in 
urban Bangladesh that supported the safety of a 
Russian-backbone LAIV.8 We have now done a clinical 
eﬃ  cacy trial to investigate the beneﬁ t of a single-dose 
Russian-backbone LAIV in children in urban and rural 
sites in Bangladesh.
Methods
Study design
This was a two-site, randomised, double-blind, placebo-
controlled, parallel-group clinical trial. The study was 
done at two demographic surveillance sites of the 
International Centre for Diarrhoeal Disease Research, 
Dhaka, Bangladesh: one in urban Kamalapur and one in 
rural Matlab. The study was approved by the ethics 
review committees of the International Centre for 
Diarrhoeal Disease Research, and by the Western 
Institutional Review Board, Puyallup, WA, USA. 
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Participant safety was overseen by an independent 
international data safety monitoring board that was 
convened by the study’s sponsor, PATH, Seattle, WA, 
USA, and a local data safety monitoring board convened 
by the International Centre for Diarrhoeal Disease 
Research. The study complied with the principles of the 
Declaration of Helsinki, and was done in compliance 
with Good Clinical Practice guidelines.
Participants
Healthy children aged 2–4 years who lived in either of the 
two demographic surveillance areas were eligible for 
enrolment if a parent or legal guardian provided written 
informed consent and the family was not expecting to 
migrate out of the area during the study. In Kamalapur, 
we approached parents of eligible children during weekly 
ﬁ eld visits in households previously selected by cluster 
randomisation for active surveillance. In Matlab, we 
approached parents of eligible children as determined by 
our demographic surveillance system by visiting their 
households. Exclusion criteria were the same as in the 
previous phase 2 study,8 and included serious, active 
medical disorders and having previously received any 
inﬂ uenza vaccine. The complete list of eligibility criteria 
is provided in the appendix.
Randomisation and masking
The random allocation sequence was computer generated 
by PATH staﬀ  not involved with the trial, using a ratio for 
LAIV and placebo of 2:1 and block sizes of three. The 
sequence was delivered to the Serum Institute of India, 
Pune, India, where it was used to label the vaccine and 
placebo syringes, which were identical in appearance 
except for the allocation numbers. The labelled syringes 
of vaccine and placebo were shipped to Bangladesh 
for use.
Study vaccine and placebo
The syringes were used to ﬁ ll spray devices with vaccine 
or placebo. Each dose was 0·5 mL, with half delivered 
into each nostril. The LAIV was 2012–13 Northern 
Hemisphere formulation (Nasovac-S, Serum Institute of 
Research in context
Evidence before this study
Cold-adapted, temperature-sensitive live attenuated inﬂ uenza 
vaccines (LAIVs) have been developed in the USA and Russia. 
These vaccines contain viruses produced by reassorting master 
donor viruses (A/Ann Arbor/6/60 and B/Ann Arbor/1/66 or 
A/Leningrad/134/17/57 and B/USSR/69/60, respectively) with 
viruses recommended by WHO or the US Public Health Service. 
Decisions are based on the expected circulation in the 
forthcoming northern or southern hemisphere inﬂ uenza season. 
LAIVs based on Ann-Arbor-derived strains are approved for use in 
children ages 2 years and older, and those based on the 
Russian-derived strains are approved for single-dose 
administration to children aged 3 years and older. Through a 
WHO agreement, manufacturers in several developing countries 
have access to Russian-derived vaccine strains for production of 
their own LAIVs. The Serum Institute of India, Pune, India, is one 
such manufacturer. Its LAIV is approved for use in children aged 
2 years and upwards. Policy decisions and sustainable use of LAIVs 
in developing countries will depend on the generation of data 
that show their eﬃ  cacy in representative populations. We 
searched PubMed from Jan 1, 1980, to Jan 1, 2016, for eﬃ  cacy 
trials assessing protection achieved with the use of LAIVs in 
children, using the search terms, “human inﬂ uenza”, “vaccines, 
attenuated”, and “children”. LAIVs have been studied primarily in 
developed countries in Europe and Asia and in the USA. Use of the 
Ann-Arbor-derived LAIV in children younger than 72 months was 
studied, with culture conﬁ rmation of illness, in several trials from 
1996 to 2005 in these regions plus one study in South Africa in 
children aged from 6 up to 36 months. These studies were done 
under Good Clinical Practice guidelines. In nearly all studies, 
protection was signiﬁ cant. Before those studies, ﬁ ve studies of 
Russian-derived LAIVs had been done in the Soviet Union and 
Cuba, primarily in 1986–91. These included nearly 
28 000 children aged 3–6 years. These studies used serological 
conﬁ rmation of illness and were done before Good Clinical 
Practice standards were introduced for trials. Moreover, except for 
one study in Senegal, no eﬃ  cacy trials of Russian-derived LAIVs 
had been done in developing countries. We found one 
case-control study assessing the clinical protection of a 
single-dose monovalent Serum Institute of India LAIV containing 
vaccine virus antigenically similar to pandemic A/H1N1 (2009).
Added value of this study
Lower respiratory tract disease caused by viral infections is 
common among young children in Bangladesh. LAIVs could 
potentially reduce some of this morbidity by preventing 
primary inﬂ uenza disease, its complications, or both. 
The feasibility of inﬂ uenza immunisation in Bangladesh would 
be increased if a single-dose LAIV provided protection. In our 
randomised trial of LAIV done exclusively among children in 
Bangladesh, we showed signiﬁ cant protection against 
PCR-conﬁ rmed inﬂ uenza illness in children aged 2–4 years. 
Implications of all the available evidence
Russian-backbone LAIV provided laboratory-conﬁ rmed 
protection in a low-resource setting, in rural and urban sites. This 
ﬁ nding suggests that single-dose LAIVs could be the optimum 
choice for protection against inﬂ uenza virus in paediatric 
populations in Asia. We are uncertain why the single-dose LAIV 
was protective in Bangladesh but not in Senegal, where no 
eﬃ  cacy was seen, but this diﬀ erence emphasises the variability in 
responses to inﬂ uenza vaccine and the need for testing in 
multiple populations and, ideally, in multiple seasons. 
See Online for appendix
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India, lot 167E2002) and contained A/California/7/2009 
(H1N1)-like, A/Victoria/361/2011 (H3N2)-like, and 
B/Wisconsin/1/2010 (Yamagata lineage)-like reassortants. 
The placebo was the vaccine vehicle without the virus 
components (Serum Institute of India, lot E9001PCB). 
The sprays were administered to each child according to 
the manufacturer’s recommendations.9
Procedures
Participants were given one dose of study vaccine or 
placebo in the clinic and asked to remain for 30 min 
after administration, under the supervision of trained 
study nurses. Field workers did daily home visits up to 
day 4 after vaccination to monitor solicited events, 
unsolicited events, protocol-deﬁ ned wheezing illness 
(PDWI), and serious adverse events (SAEs). If children 
presented at the clinic on days 4–7 with symptoms, 
these were included in solicited events. Thereafter 
children were monitored weekly at home by trained 
ﬁ eld workers. All children identiﬁ ed through home-visit 
surveillance as meeting protocol-deﬁ ned criteria for 
physician assess ment (signs of illness) were assessed by 
a study physician in the clinic according to standardised 
criteria. If children met protocol-deﬁ ned criteria for 
specimen collection and presented within 7 days of 
illness onset, a nasopharyngeal wash specimen was 
collected for testing by real-time RT-PCR for evidence of 
inﬂ uenza virus infection, according to the WHO 
laboratory protocol.10
The physician assessment criteria included the 
presence of at least one major or two minor signs. 
Major signs were fever (axillary temperature ≥38·0°C), 
tachypnoea (≥40 breaths per min), danger signs (chest 
wall indrawing, lethargy, cyanosis, inability to drink, 
convulsions), diﬃ  culty breathing, noisy breathing, ear 
pain, or ear discharge. Minor signs were subjective 
fever (feverishness), cough, rhinorrhoea, sore throat, 
myalgia or arthralgia, chills, headache, irritability or 
decreased activity, or vomiting. The criteria for 
specimen collection were two or more of axillary 
temperature 37·5°C or higher, cough, sore throat, and 
runny nose or nasal congestion present on the same 
day, or any of fever (axillary temperature ≥38·0°C), 
upper respiratory illness (axillary temperature ≥37·5°C 
with cough and rhinorrhoea), pneumonia, acute otitis 
media, meningitis, or sepsis, as diagnosed by the 
physician.4,11
Assays were done at the International Centre for 
Diarrhoeal Disease Research, Bangladesh, as previously 
described.12,13 Antigenic characterisation of positive 
samples was done at the virology laboratory at the 
International Centre for Diarrhoeal Disease Research.13 
Genotyping was done to distinguish vaccine virus from 
wild-type virus at the Department of Virology, Institute of 
Experimental Medicine, Saint Petersburg, Russia, using 
specimens that were PCR positive within 14 days of 
vaccination.14
Outcomes
The primary eﬃ  cacy endpoint was symptomatic, 
laboratory-conﬁ rmed inﬂ uenza virus infection with 
vaccine-matched strains up to December, 2013. The 
secondary eﬃ  cacy endpoint was symptomatic, laboratory-
conﬁ rmed inﬂ uenza virus infection with any inﬂ uenza 
virus strain.
Safety endpoints included immediate reactions 
occurring within 30 min of taking the vaccine, solicited 
reactions (nasal congestion, runny nose, ear pain, cough, 
sore throat, headache, fever, tachypnoea, muscle or joint 
pain, chills, irritability or decreased activity, and vomiting) 
and unsolicited adverse events occurring in the ﬁ rst 4 days 
after vaccination, as assessed by daily home visits, and up 
to day 7, as captured in the clinic. Severity of adverse events 
was graded as mild, moderate, severe, and life threatening. 
PDWI was deﬁ ned as an illness meeting the physician 
assessment criteria and characterised by a long, high-
pitched whistling or musical sound on expiration heard by 
auscultation over the lung ﬁ elds. Severity of PDWI was 
graded by study physicians as mild (wheezing illness 
without other ﬁ ndings associated with moderate or greater 
severity disease), moderate (nasal ﬂ aring, chest in-drawing, 
or pulse oximetry ≥90% to <95%), severe (dyspnoea at rest 
causing inability to perform usual activities or pulse 
oximetry <90%), or life threatening. This deﬁ nition was 
designed to be similar to the deﬁ nitions of medically 
important wheezing used in previous trials8,15 and to 
exclude incidental wheezing illness without other clinically 
important signs or symptoms.
Statistical analyses
Assuming 60% eﬃ  cacy, we calculated that 57 symptomatic, 
laboratory-conﬁ rmed inﬂ uenza virus infections would be 
needed to test the hypothesis that LAIV eﬃ  cacy was 
greater than 0 with a one-sided type I error of less than 
1811 children enrolled and screened
50 excluded (did not meet inclusion 
or met exclusion criteria)
1761 randomised
1174 (800 Kamalapur, 374 Matlab) 
assigned LAIV 
93 excluded
2 died (1 Kamalapur, 1 Matlab) 
20 lost to follow-up (20 Kamalapur) 
71 moved away (63 Kamalapur, 8 Matlab) 
1081 (716 Kamalapur, 365 Matlab) 
completed follow-up
587 (400 Kamalapur, 187 Matlab) 
assigned placebo
31 excluded
7 lost to follow-up (7 Kamalapur) 
24 moved away (24 Kamalapur) 
556 (369 Kamalapur, 187 Matlab) 
completed follow-up
Figure 1: Trial proﬁ le
LAIV=live attenuated inﬂ uenza vaccine.
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2·5% and power of at least 90% (exact type I error and 
power 1·9% and 91·5%, respectively). On the basis of this 
number and assuming 6% inﬂ uenza illness incidence in 
the placebo group and that 90% of children would be 
assessable, we estimated that we would need a total 
sample size of 1761 enrolled and vaccinated children.
The primary objective was to estimate the eﬃ  cacy of 
LAIV to reduce the incidence of symptomatic, laboratory-
conﬁ rmed inﬂ uenza virus infection with vaccine-matched 
strains, compared with placebo. Vaccine eﬃ  cacy, expressed 
as a percentage, was deﬁ ned as 1 minus the relative rate of 
inﬂ uenza in the LAIV group compared with that in the 
placebo group. Eﬃ  cacy with 95% CIs was computed with a 
binomial distribution of LAIV cases. We used Fisher’s exact 
test to obtain two-sided p values for the test of the null 
hypothesis of zero vaccine eﬃ  cacy. Primary eﬃ  cacy 
analyses and summaries were done on a per-protocol basis. 
The per-protocol analysis set included all children who met 
the inclusion criteria, were randomised, and received one 
dose of study vaccine or placebo, and who remained in the 
study area for at least 8 days after vaccination. Analyses 
were based on the ﬁ rst case of inﬂ uenza occurring from 
study day 8 onwards until Dec 31, 2013. Supportive analyses 
were done in the total vaccinated cohort (ie, all children 
who were randomised and received one dose of vaccine or 
placebo, irrespective of how long they stayed in the study 
area). All analyses excluded samples identiﬁ ed as 
containing vaccine virus.
Safety was assessed in the total vaccinated cohort and 
was described as the proportion (95% CI) of children 
who had any reaction or adverse event. Diﬀ erences 
between groups were calculated, including two-sided 
p values, with Fisher’s exact test. Statistical analyses were 
done with SAS version 9.3. This study is registered with 
ClinicalTrials.gov, number NCT01797029.
Role of the funding source
The funder had no role in the study, data collection, data 
analysis, data interpretation, or the writing of the report. 
The corresponding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication. 
Kamalapur Matlab All
LAIV (n=800) Placebo (n=400) LAIV (n=374) Placebo (n=187) LAIV (n=1174) Placebo (n=587) Total (n=1761)
Mean (range) age 
(months)
42·7 (24–59) 42·3 (24–59) 42·2 (24–59) 41·8 (24–59) 42·5 (24–59) 42·1 (24–59) 42·4 (24–59)
Age group (years)
≥2 to <3 248 (31·0%) 138 (34·5%) 105 (28·1%) 53 (28·3%) 353 (30·1%) 191 (32·5%) 544 (30·9%)
≥3 to <4 229 (28·6%) 105 (26·3%) 134 (35·8%) 69 (36·9%) 363 (30·9%) 174 (29·6%) 537 (30·5%)
≥4 to <5 323 (40·4%) 157 (39·3%) 135 (36·1%) 65 (34·8%) 458 (39·0%) 222 (37·8%) 680 (38·6%)
Sex
Male 410 (51·3%) 191 (47·8%) 175 (4·8%) 90 (48·1%) 585 (49·8%) 281 (47·9%) 866 (49·2%)
Female 390 (48·8%) 209 (52·3%) 199 (53·2%) 97 (51·9%) 589 (50·2%) 306 (52·1%) 895 (50·8%)
Underweight (weight for age malnutrition)*
None 203 (25·4%) 103 (25·8%) 106 (28·3%) 48 (25·7%) 309 (26·3%) 151 (25·7%) 460 (26·1%)
Mild 324 (40·5%) 173 (43·3%) 162 (43·3%) 84 (44·9%) 486 (41·4%) 257 (43·8%) 743 (42·2%)
Moderate 219 (27·4%) 105 (26·3%) 91 (24·3%) 43 (23·0%) 310 (26·4%) 148 (25·2%) 458 (26·0%)
Severe 54 (6·8%) 19 (4·8%) 15 (4·0%) 12 (6·4%) 69 (5·9%) 31 (5·3%) 100 (5·7%)
Stunting (height for age malnutrition)*
None 152 (19·0%) 84 (21·0%) 111 (29·7%) 47 (25·1%) 263 (22·4%) 131 (22·3%) 394 (22·4%)
Mild 275 (34·4%) 144 (36·0%) 140 (37·4%) 81 (43·3%) 415 (35·3%) 225 (38·3%) 640 (36·3%)
Moderate 257 (32·1%) 127 (31·8%) 95 (25·4%) 50 (26·7%) 352 (30·0%) 177 (30·2%) 529 (30·0%)
Severe 116 (14·5%) 45 (11·3%) 28 (7·5%) 9 (4·8%) 144 (12·3%) 54 (9·2%) 198 (11·2%)
Wasting (weight for height malnutrition)*
None 495 (61·9%) 249 (62·3%) 209 (55·9%) 100 (53·5%) 704 (60·0%) 349 (59·5%) 1053 (59·8%)
Mild 243 (30·4%) 125 (31·3%) 120 (32·1%) 65 (34·8%) 363 (30·9%) 190 (32·4%) 553 (31·4%)
Moderate 60 (7·5%) 20 (5·0%) 42 (11·2%) 21 (11·2%) 102 (8·7%) 41 (7·0%) 143 (8·1%)
Severe 2 (0·3%) 6 (1·5%) 3 (0·8%) 1 (0·5%) 5 (0·4%) 7 (1·2%) 12 (0·7%)
Asthma or wheezing illness
Previous hospital 
admission 
58 (7·3%) 20 (5·0%) 0 0 58 (4·9%) 20 (3·4%) 78 (4·4%)
Previous treatment 242 (30·3%) 134 (33·5%) 0 0 242 (30·3%) 134 (33·5%) 376 (21·4%)
LAIV=live attenuated inﬂ uenza vaccine. *Z score, mild (–2 to <–1), moderate (–3 to <–2), or severe (<–3). 
Table 1: Baseline characteristics
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Figure 2: Inﬂ uenza circulation in the study area overall and in Kamalapur and Matlab, by type and subtype or lineage, in weeks 9–52 of 2013
(A) The whole study area. (B) Kamalapur. (C) Matlab. Circulating and vaccine B strains were mismatched and, therefore, did not contribute to vaccine eﬃ  cacy 
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Results
Study population
Of 1811 children enrolled, 1761 received vaccine or 
placebo between Feb 27 and April 9, 2013 (total vaccinated 
analysis set), of whom 1637 were followed up for study 
outcomes until Dec 31, 2013 (ﬁ gure 1). No participants 
were lost to follow-up before day 8. 1637 (92·9%) of study 
participants completed home follow-up visits to 
December, 2013, 1081 (92·0%) of those who received 
LAIV and 556 (94·7%) of those who received placebo 
(p=0·048).
Baseline demographic characteristics and medical 
history were similar in the two study groups (table 1), 
although diﬀ erences were noted between the urban 
Kamalapur site and the rural Matlab site. Nearly twice as 
many children had severe stunting in Kamalapur as in 
Matlab, and previous medical treatment for asthma or 
wheezing illness was 31·3% in Kamalapur, including 
6·5% who were admitted to hospital, compared with no 
children in Matlab.
Inﬂ uenza circulated in the study area from February to 
November, 2013 (ﬁ gure 2). Symptomatic, laboratory-
conﬁ rmed inﬂ uenza illness due to vaccine-matched 
inﬂ uenza viruses from 8 days after vaccination onwards 
was seen in 79 (6·7%) participants in the LAIV group and 
93 (15·8%) participants in the placebo group, giving a 
vaccine eﬃ  cacy of 57·5% (95% CI 43·6–68·0; table 2). In 
the strain-speciﬁ c analysis in the per-protocol population 
(table 2), eﬃ  cacy was 50–60% for the H3N2 and H1N1 
strains. Only three children had vaccine-matched 
B/Yamagata strains isolated during the study. The attack 
rate for the mismatched B/Victoria lineage was 
statistically similar in the two study groups and, 
therefore, there was no vaccine eﬃ  cacy against 
mismatched B lineage viruses. When all strains of 
inﬂ uenza virus were analysed in the per-protocol 
population, including the mismatched B strains, vaccine 
eﬃ  cacy was 41·0% (table 2). Results were similar in the 
total vaccinated cohort (appendix). When vaccine eﬃ  cacy 
was assessed by study site, the rural Matlab site had 
higher inﬂ uenza illness attack rates and higher vaccine 
eﬃ  cacy than the urban Kamalapur site (table 2). In a 
post-hoc analysis, children with a history of asthma or 
wheezing illness in Kamalapur had a lower point 
estimate of eﬃ  cacy than children without such a history 
(table 2).
No immediate reactions were seen after vaccine or 
placebo were administered. In the 7 days after receiving 
the study drug or placebo, the most common local and 
systemic events were runny nose, cough, and tachypnoea 
(table 3). Nearly all reactions were mild and similar 
proportions of children were aﬀ ected in the vaccine and 
placebo groups. Among children with any history of 
asthma or wheezing illness, the frequency of PDWI was 
very similar in the LAIV and placebo groups, and among 
those without such a history, more in the placebo group 
than in the LAIV group had PDWI (table 3). No 
proportions of children with PDWI were signiﬁ cantly 
higher in the LAIV than in the placebo group when 
assessments were done by age group, site, site and age 
group, or history of asthma or wheezing illness at 
baseline. Two children died in the vaccine group during 
the study, both owing to drowning. Neither death was 
deemed to be related to vaccination.
Discussion
This prospective trial of a single-dose Russian-backbone 
LAIV with intranasal delivery showed vaccine eﬃ  cacy in 
children in Bangladesh with a good safety proﬁ le. These 
ﬁ ndings add important information to the data available 
on this vaccine because the original licensing studies 
done in Russia took place before PCR was used to 
conﬁ rm inﬂ uenza virus infection, and licensing in India 
did not require laboratory-conﬁ rmed prospective eﬃ  cacy 
studies. LAIV was eﬃ  cacious against infection with 
circulating inﬂ uenza H1N1pdm09 and H3N2 viruses, 
which are antigenically similar to the vaccine 
components. LAIV was not eﬃ  cacious against infection 
with circulating B strains, as most were mismatched to 
the lineage in the vaccine.
When diﬀ erences in study year, and thus vaccine and 
circulating strains, are taken into account, our 
primary eﬃ  cacy against vaccine-matched strains of 
57·5% (95% CI 43·6–68·0) is very close to the 59·9% 
(31·1–77·4) eﬃ  cacy against vaccine-matched strains 
reported for a single-dose Ann-Arbor-based LAIV given 
to children aged 2–3 years in southeast Asia.16 
LAIV (n=1174) Placebo (n=587) Vaccine eﬃ  cacy 
(95% CI)
Number of 
infections 
Attack 
rate (%)
Number of 
infections 
Attack 
rate (%)
Whole study population (n=1761)
All vaccine-matched strains 79 6·7% 93 15·8% 57·5% (43·6 to 68·0)
All strains 170 14·5% 144 24·5% 41·0% (28·0 to 51·6)
H1N1 21 1·8% 21 3·6% 50·0% (9·2 to 72·5)
H3N2 57 4·9% 72 12·3% 60·4% (44·8 to 71·6)
B/Yamagata (vaccine-matched) 2 0·2% 1 0·2% 0% (–1001·0 to 90·9)
B/Victoria (unmatched) 58 4·9% 31 5·3% 6·5% (–43·0 to 38·8)
Kamalapur (n=1200)†
All vaccine-matched strains 56 7·0% 52 13·0% 46·2% (23·0 to 62·4)
With history of asthma or wheeze‡ 22 8·9% 17 12·6% 29·0% (–29·0 to 60·9)
Without history of asthma or wheeze 34 6·1% 35 13·2% 53·4% (27·2 to 70·3)
All strains 103 12·9% 79 19·8% 34·8% (14·8 to 50·1)
Matlab (n=561)§
All vaccine-matched strains 23 6·1% 41 21·9% 72·0% (54·7 to 82·6)
All strains 67 17·9% 65 34·8% 48·5% (30·9 to 61·5)
LAIV=live attenuated inﬂ uenza vaccine. *Includes laboratory-conﬁ rmed inﬂ uenza infections occurring from 8 days 
onwards after receiving vaccine or placebo. †n=800 in the LAIV group, n=400 in the placebo group. ‡Vaccine eﬃ  cacy 
analyses including history of asthma or wheezing could only be interpreted for the Kamalapur study site where history 
was identiﬁ ed at baseline. No participants at the Matlab site indicated a history of asthma or wheeze. §n=347 in the 
LAIV group, n=187 in the placebo group.
Table 2: Vaccine eﬃ  cacy in the per-protocol population* 
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Among children aged 2 years in South Africa and 
South America, an Ann-Arbor-backbone LAIV had 71·5% 
(95% CI 52·9–83·4) and 81·8% (66·8–90·8) eﬃ  cacy 
against laboratory-conﬁ rmed inﬂ uenza illness after one 
or two doses, respectively.17 As the vaccine used in our 
study is licensed for single-dose administration,10 we did 
not include a two-dose group. The increased cost and 
logistical challenges of a second dose would need to be 
weighed against any incremental beneﬁ t in low-resource 
settings. If the Russian-backbone vaccine were integrated 
into vaccine programmes in most low-income and 
middle-income countries, use of one dose would be likely 
to have substantial logistical and cost advantages over a 
two-dose regimen. Future studies could explore the 
beneﬁ t of a second dose of vaccine in children receiving 
inﬂ uenza vaccine for the ﬁ rst time. 
The proportions of children in our study who received 
LAIV and had inﬂ uenza illness were similar in 
Kamalapur (7·0%) and Matlab (6·1%), but the attack rate 
was higher in the Matlab placebo group than in the 
Kamalapur placebo group (21·9% vs 13·0%, table 2). 
Although the 95% CIs overlapped, vaccine eﬃ  cacy for 
vaccine-matched strains was higher in Matlab than in 
Kamalapur in the per-protocol analysis set (72·0%, 95% CI 
54·7–82·6 vs 46·2%, 23·0–62·4), possibly because of a 
lower force of infection in the rural setting than in the 
densely populated urban setting. Furthermore, the 
enrolled population in Kamalapur might have been less 
healthy than those in Matlab, since higher proportions of 
children had severe stunting and asthma or wheezing 
illness.
We chose our vaccination period to ensure children were 
vaccinated before the onset of peak inﬂ uenza season, 
which is typically between April and September.2,4 The 
eﬃ  cacy we showed against the A(H1N1)pdm09 viruses is 
important because several observational studies of the 
Ann-Arbor-backbone LAIV in the USA in the 2013–14 and 
2015–16 seasons and the Russian-backbone LAIV in 
Senegal showed no such eﬃ  cacy.18–20 The same vaccine lot 
was used for this and the Senegal trial, and the storage 
conditions at both sites were well monitored and well 
maintained. Thus, a vaccine-speciﬁ c cause for the 
diﬀ erence in results seems unlikely. Inﬂ uenza vaccine is 
not widely used in Bangladesh. Whether the lack of 
previous exposure to inﬂ uenza vaccine, use of a diﬀ erent 
vaccine formulation than had been used previously, or 
both, aﬀ ected inﬂ uenza A(H1N1) eﬃ  cacy in our 
Bangladesh population diﬀ erently from that in the same 
period in the USA is unclear. It is likely, however, that 
excluding children who had previously been vaccinated 
ensured generalisability of our ﬁ ndings to the wider 
Bangladesh population. Unfortunately, the generalisability 
of our ﬁ ndings to other settings is uncertain.
The major limitation of our study is that it focused on 
clinical eﬃ  cacy and did not include immunogenicity 
measurements. At the time of this study, the preferential 
use of LAIVs was being considered in several countries 
due to superior performance in young children in 
LAIV (n=1174) Placebo (n=587) Whole population (n=1761)
Mild Moderate Severe Mild Moderate Severe Mild Moderate Severe 
Local and systemic reactions
Fever (≥38°C) 17 (1·4%) 20 (1·1%) 0 8 (1·4%) 8 (1·4%) 0 25 (1·4%) 28 (1·6%) 0
Nasal congestion 1 (0·1%) 0 0 1 (0·2%) 0 0 2 (0·1%) 0 0
Runny nose 68 (5·8%) 0 0 39 (6·6%) 0 0 107 (6·1%) 0 0
Cough 72 (6·1%) 1 (0·1%) 0 43 (7·3%) 0 0 115 (6·5%) 1 (0·1%) 0
Sore throat 4 (0·3%) 0 0 2 (0·3%) 0 0 6 (0·3%) 0 0
Ear pain 2 (0·2%) 0 0 3 (0·5%) 0 0 5 (0·3%) 0 0
Headache 0 0 0 1 (0·2%) 0 0 1 (0·1%) 0 0
Vomiting 4 (0·3%) 0 0 5 (0·9%) 1 (0·2%) 0 9 (0·5%) 1 (0·1%) 0
Chills 0 0 0 0 0 0 0 0 0
Irritability or decreased activity 1 (0·1%) 0 0 0 0 0 1 (0·1%) 0 0
Muscle/joint pain 3 (0·3%) 1 (0·1%) 0 0 0 0 3 (0·2%) 1 (0·1%) 0
Tachypnoea* 77 (6·6%) 9 (0·5%) 0 53 (9·0%) 1 (0·2%) 0 130 (7·4%) 10 (0·6%) 0
Protocol-deﬁ ned wheezing illness 
Days 0–7 4 (0·3%) 0 0 1 (0·2%) 0 0 5 (0·3%) 0 0
Days 8–42 16 (1·4%) 0 0 9 (1·5%) 0 0 25 (1·4%) 0 0
Day 43 to 6 months 38 (3·2%) 1 (0·1%) 0 31 (5·3%) 1 (0·2%) 0 69 (3·9%) 2 (0·1%) 0
Day 0 to 6 months 53 (4·5%) 1 (0·1%) 0 37 (6·3%) 1 (0·2%) 0 90 (5·1%) 2 (0·1%) 0
Anytime† 78 (6·6%) 3 (0·3%) 0 46 (7·8%) 4 (0·7%) 0 124 (7·0%) 7 (0·4%) 0
LAIV=live attenuated inﬂ uenza vaccine. *Mild 31–40 breaths per min, moderate 41–50 breaths per min, and severe ≥51 breaths per min. †Including events occurring >6 months 
after vaccination. 
Table 3: Local and systemic reactions in the 7 days after vaccination and protocol-deﬁ ned wheezing illness at any time
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randomised trials over inactivated vaccines. Our study was 
done before the studies in Senegal and the USA showed 
lack of eﬃ  cacy for A(H1N1)pdm09 strains. In retrospect, 
information on the immunogenicity and replicative ability 
of the vaccine used in this study might have informed our 
interpretation of the variation in results between settings 
that subsequently emerged. However, the overall 
usefulness of immunogenicity data in this context is 
uncertain because of the diﬃ  culty in identifying protective 
immunological correlates for LAIVs in previous studies.21
In a previous study of 300 children in Kamalapur, we 
prospectively assessed wheezing endpoints for the 
single-dose Russian-backbone LAIV.8 In this larger study, 
background wheezing was higher in urban Kamalapur 
(9·1%) than in rural Matlab (3·9%), but increases in or 
worsening of wheezing-related illness were not seen in 
either site. These results are reassuring, particularly in 
combination with a similar lack of wheezing signal in the 
Senegal study,18 and support careful assessment of the 
Russian-backbone LAIV in younger age groups. Previous 
data from Bangladesh show high attack rates and severe 
illness in young children3–5,7 particularly those younger 
than 2 years.4,6
This study corroborates data obtained over many years 
in urban and rural Bangladesh, which have shown 
sustained circulation of multiple inﬂ uenza strains and 
associated high clinical attack rates.2–7,12,22–24 Overall, 24·5% 
of children in our study had laboratory-conﬁ rmed 
inﬂ uenza illness (any strain) during the course of this 
trial, including over a third (34·8%) of children at the 
rural Matlab site. Circulation of B viruses was common, 
which suggests that the use of a quadrivalent vaccine 
with eﬃ  cacy against both B lineages might further 
increased the magnitude of the eﬀ ect.
Our results support the use of a single-dose LAIV to 
prevent medically attended lower respiratory tract illness 
in young children in Bangladesh. Large multisite trials of 
vaccines in children done over multiple years could 
improve measurement of the eﬀ ects of inﬂ uenza 
vaccines, establish the burden of severe inﬂ uenza disease 
in young children, and inform policy and ﬁ nancing 
decisions.25 Improved understanding of population-
based diﬀ erences in inﬂ uenza vaccine performance is 
crucial to designing eﬀ ective public health programmes 
in low-resource settings.
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